Swiss equities attractive amid geopolitical uncertainty, says UBS By Investing.com

UBS rates Swiss equities as attractive: SMI forward P/E ~16x vs long-term average 15.8x and a sustainable dividend yield >3%. UBS central SMI target 14,000 by Dec 2026 (current 12,421), upside 15,000 and downside 10,500; expects mid-single-digit dividend growth for FY2025 in spring 2026 and potential high-single-digit profit growth in 2026 under the upside scenario. UBS flags easing negative currency effects from Q2 2026 and highlights structural opportunities in longevity and energy-transition-related industrials, while noting geopolitical and CHF appreciation risks.

Analysis

Switzerland’s market is effectively a play on structural defense (large caps with pricing power and cash returns) versus cyclicals tied to industrial capex and export volumes. The non-obvious transmission is via currency and client payment terms: a stronger franc not only reduces reported revenues for exporters, it compresses working-capital dynamics (longer collection in foreign currencies becomes a margin leak) and can force more aggressive buyback timing among banks and asset managers to shore up EPS.

Second-order winners are balance-sheet-rich names that can convert excess cash into buybacks or targeted M&A without FX exposure — they also become takeover targets for foreign strategics if currency moves make Switzerland cheaper. Conversely, supply-chain dependent industrials exposed to Chinese and European manufacturing cycles will see order-book volatility amplified because local pricing is sticky while input costs and FX move quickly.

Timing matters: the next 3–12 months are a regime testing period where rates, geopolitics, and FX will dominate realized returns; over multiple years, demographic-driven domestic demand (healthcare/“longevity” services and specialized industrial automation for energy transition) should raise earnings resiliency but also concentrate risk in a smaller set of winners. Liquidity and positioning risk are elevated — crowded yield-seeking can reverse sharply if macro momentum stalls, creating 15–25% drawdowns in previously “defensive” stocks within weeks.

Key Decisions for Investors

• Long NESN (Nestlé) 12-month buy-and-hold with 5% position sizing; hedge ~30–50% of CHF revenue beta with USD/CHF call options or EUR/CHF puts. Rationale: high cash conversion and low cyclicality provide downside protection; target asymmetric upside of 15–25% vs downside 8–12% from a franc shock.
• Pair trade: Long ROG (Roche) / Short ABB on equal notional for 6–12 months. This reduces macro-beta while expressing a preference for healthcare pricing power over industrial order volatility. Look to enter after major macro headlines calm (2–6 trading days) and trim on +15% move or widen if CHF strengthens >5%.
• Buy USD/CHF 3–6 month call spread (long USD/CHF, short deeper OTM) to hedge portfolio-level franc appreciation risk; cost-limited hedge that pays if franc re-rates harder, capping premium while providing protection for exporters-heavy sleeves.
• Initiate a tactical overweight in high-quality Swiss mid-caps with visible dividend growth using covered-call overlays (sell 3–6 month calls at 10–15% OTM) to harvest yield while limiting downside. Target 4–6 names, cap exposure to 6% per name, and remove overlays if implied vol drops >30% or after major macro repricing.